Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 438, 1076-1077 (22 December 2005) | doi:10.1038/4381076a; Published online 21 December 2005
Merck opts for shake-up to clear drug pipeline
Top of page
Abstract
The failure of the painkiller Vioxx and a lack of new products leaves the world's third-largest drug company in the lurch. Emma Marris reports.
Substance P is an intriguing neurotransmitter molecule that has frustrated a generation of pharmacologists. For decades, it has been known to be highly active in both the brain and the gut — but it cannot easily be lured into the medicine cabinet.
To read this story in full you will need to login or make a payment (see right).